Dewilde S, et al. People Diagnosed with Myasthenia Gravis have Lower health-related quality of life and Need More Medical and Caregiver Help in Comparison to the General Population: Analysis of Two Observational Studies. Adv Ther. Vol 40, 4377–4394 (2023). Available at: https://doi.org/10.1007/s12325-023-02604-z Last accessed: June 2024.
[4]
Mahic, et al. Healthcare resource use in myasthenia gravis: a US health claims analysis. Ther Adv Neurol Disorders (2023). Available at: https://doi.org/10.1177/17562864221150327 Last accessed: June 2024.
[5]
Daum P et al. Perioperative management of myasthenia gravis. BJA Education (2021) 21(11): 414e419
Mishra A, et al. Myasthenia Gravis: A Systematic Review. Cureus (2023) 15(12): e50017. DOI 10.7759/cureus.50017.
[8]
Luo H, Xie S, Ma C, Zhang W, Tschöpe C, Fa X, Cheng J, Cao J. Correlation Between Thymus Radiology and Myasthenia Gravis in Clinical Practice. Front Neurol. 2019 Jan 15;9:1173. doi: 10.3389/fneur.2018.01173. PMID: 30697185; PMCID: PMC6340958.
[9]
Chen J, Tian D-C, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study. The Lancet Regional Health - Western Pacific. 2020;5(100063). https://doi.org/10.1016/j.lanwpc.2020.100063.
[10]
Lazaridis K, et al. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front Immunol. 2020 Feb 14;11:212. doi: 10.3389/fimmu.2020; 00212. Last accessed: June 2024.
Jackson et al. Understanding the symptom burden and impact of myasthenia gravis from the patient’s perspective: A qualitative study. Neurology and Therapy. 2022;12:1; 107–128. Available at: https://doi.org/10.1007/s40120-022-00408-x.